Neuralink, a company developing brain-computer interface (BCI) devices aimed at restoring independence to people with paralysis caused by conditions such as amyotrophic lateral sclerosis (ALS), has tested a new implant approach in which electrode threads were inserted through the dura without cutting it open. The dura is the…
Neuralink tests brain implant approach that leaves protective layer intact
A University of Melbourne spinout company is developing a less invasive brain-computer interface that could one day allow people with impaired speech, including those with amyotrophic lateral sclerosis (ALS), to communicate by attempting to say words. Unlike many current brain-computer interface prototypes, which can involve invasive surgery…
My husband, Todd, and I sat on the patio on a perfect summer day in Michigan’s Upper Peninsula. It was in the 70s and sunny, with a brisk wind that kept the mosquitoes and biting flies away. We looked out beyond our backyard to a field that had been a…
Incorporating muscle assessments from whole-body MRIs (WB-MRIs) into the diagnostic process for amyotrophic lateral sclerosis (ALS) may help identify the condition with a greater degree of certainty, according to a study from France. ALS causes damage to specialized nerve cells called motor neurons. Some criteria for diagnosing ALS…
I’m always on the lookout for examples of how other people successfully handle life’s big and little speed bumps. Because I need all the inspiration I can get, especially since my biggest speed bump is living with ALS. Little ALS bumps happen almost every day, constantly testing my resilience.
Oral amyotrophic lateral sclerosis (ALS) treatment PrimeC significantly reduced levels of TDP-43, a protein that abnormally accumulates in nearly all ALS cases, in a Phase 2b clinical trial. The PARADIGM study met its main efficacy goal of lowering TDP-43 levels in nerve cells relative to a placebo after six months.
Former NFL running back Chris Johnson, whose historic 2,000 rushing yards in a season earned him the nickname CJ2K, has revealed that he is living with amyotrophic lateral sclerosis (ALS), saying he hopes sharing his story will encourage earlier diagnoses, inspire more research, and give hope to others facing…
Trace Neuroscience has launched its clinical development program for TRCN-1023, an experimental treatment for amyotrophic lateral sclerosis (ALS) that is designed to restore the function of UNC13A, a protein involved in nerve-muscle communication. The global clinical program includes FUNCTION ALS, a company-sponsored Phase 1/2 clinical trial authorized…
I’m writing this column from vacation in a place I once traveled with my late husband, Jeff, long before he was diagnosed with ALS in 2018. It was a dream trip of his, and we went together for his birthday more than a decade ago. On this trip, we…
The lowest tested dose of Amylyx Pharmaceuticals‘ treatment candidate AMX0114 was found to be safe and well tolerated among people with amyotrophic lateral sclerosis (ALS) in an ongoing Phase 1 clinical trial. Biomarkers of nerve damage due to ALS remained relatively stable from the study’s start — a result…
Recent Posts
- A trip to the ER makes me thankful I still have my parenting partner
- PBS documentary on runner with ALS explores identity, caregiving
- A new wheelchair means making adjustments mentally and physically
- Real-world study sheds new light on safety of approved ALS drug
- Self-balancing robotic suit helps ALS patients practice walking